ArticleMolecular cancer research : MCR2019
Open access · hybridAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- The Roles of PTEN in Melanoma Suppression.Pigment cell & melanoma research · 2025Review
- Induced clustering of SHP2-depleted tumor cells in vascular islands restores sensitivity to MEK/ERK inhibition.The Journal of clinical investigation · 2025Article
- Proteome-wide assessment of differential missense variant clustering in neurodevelopmental disorders and cancer.Cell genomics · 2025Article
- An Unexpected Finding of a PTPN11 Germline Mutation in a Patient With a Melanocytic Lesion With a Somatic MAP2K1 Mutation. Coincidence or Not?Journal of cutaneous pathology · 2025Article
- Insights into the Molecular Mechanisms of Bushen Huoxue Decoction in Breast CancerCurrent computer-aided drug design · 2025Article
- TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway.Journal of gynecologic oncology · 2024Article
- Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancers.The Journal of clinical investigation · 2024Article
- SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.American journal of hematology · 2024Article
- Head-to-Head Comparison of CCN4, DNMT3A, PTPN11, and SPARC as Suppressors of Anti-tumor Immunity.Cellular and molecular bioengineering · 2023Article
- PTPN11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort.Journal of neuro-oncology · 2023Article
- Skewing cPLAScience signaling · 2023Article
- RETRACTED: Protein Tyrosine Phosphatase Non-Receptor 11 (International journal of molecular sciences · 2023Article
- PTPN11 Mosaicism Causes a Spectrum of Pigmentary and Vascular Neurocutaneous Disorders and Predisposes to Melanoma.The Journal of investigative dermatology · 2023Article
- Setting sail: Maneuvering SHP2 activity and its effects in cancer.Advances in cancer research · 2023Review
- Caspase 9b Drives Cellular Transformation, Lung Inflammation, and Lung Tumorigenesis.Molecular cancer research : MCR · 2022Article
- A pan-cancer analysis confirms PTPN11's potential as a prognostic and immunological biomarker.Aging · 2022Article
- The RASopathies: from pathogenetics to therapeutics.Disease models & mechanisms · 2022Review
- Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state.Computational and structural biotechnology journal · 2021Article
- Current Perspectives and Novel Strategies ofOncoTargets and therapy · 2021Review
- A compendium of mutational cancer driver genes.Nature reviews. Cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Kristen S HillDepartment of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida.
Evan R RobertsDepartment of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida.
Xue WangDepartment of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida.
Ellen MarinDepartment of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida.
Taeeun D ParkDepartment of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida.
Sorany SonDepartment of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida.
Yuan RenDepartment of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida.
Bin FangDepartment of Proteomics, Moffitt Cancer Center, Tampa, Florida.
Sean YoderMolecular Genomics Core, Moffitt Cancer Center, Tampa, Florida.
Sungjune KimDepartment of Immunology, Moffitt Cancer Center, Tampa, Florida.
Lixin WanDepartment of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida.
Amod A SarnaikDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
John M KoomenDepartment of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0002-3818-1762
Jane L MessinaDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0002-0332-0224
Jamie K TeerDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0003-4513-0282
Youngchul KimDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida.
Jie WuPeggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.ORCID 0000-0002-2864-1606
Charles E ChalfantDepartment of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, Florida.
Minjung KimDepartment of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida. kimm@usf.edu.
Moffitt Cancer Center · USUniversity of South Florida · USUniversity of Oklahoma Health Sciences Center · US
Funding
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5MTissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Wade Williams · 2018 to 2026
$27.1MThe roles of ceramide and its derivatives in A. phagocytophilum pathogenesisR01AI139072 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI CHARLES E. CHALFANT, Jason A Carlyon · 2018 to 2026
$5.7MThe utilization of photonics technology to rapidly detect bioactive lipids associated with preeclampsia developmentU01HD087198 · NICHD · VIRGINIA COMMONWEALTH UNIVERSITY · PI CHALFANT, CHARLES E., WALSH, SCOTT W · 2015 to 2015
$4.2MThe functional role of the cPLA2alpha/C1P interaction in sepsis resolutionR01HL125353 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI BROWN, RHODERICK E, CHALFANT, CHARLES E. · 2014 to 2018
$4.0MBLRD Research Career Scientist Award ApplicationIK6BX004603 · VA · VA VETERANS ADMINISTRATION HOSPITAL · PI CHALFANT, CHARLES E. · 2019 to 2025
–The role of RNA splicing in non-small cell lung cancerI01BX001792 · VA · VA VETERANS ADMINISTRATION HOSPITAL · PI CHALFANT, CHARLES E. · 2013 to 2024
–BLRD VA I01 BX001792BLRD VA IK6 BX004603NCI NIH HHS P30 CA076292NCI NIH HHS P30 CA225520NHLBI NIH HHS R01 HL125353NIAID NIH HHS R01 AI139072NICHD NIH HHS U01 HD087198
Abstract
Melanoma is one of the most highly mutated cancer types. To identify functional drivers of melanoma, we searched for cross-species conserved mutations utilizing a mouse melanoma model driven by loss of PTEN and CDKN2A, and identified mutations in
Indexed as
AnimalsCell LineDisease Models, AnimalMAP Kinase Signaling SystemMelanoma, ExperimentalMiceMice, NudeMolecular Targeted TherapyProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins B-rafBraf protein, mouseProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins B-rafPtpn11 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.